Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing.

Type I interferons (IFNs), which activate many IFN-stimulated genes (ISGs), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing anti-tumor effects. Here we report that the ISG, UBA7, is a tumor suppressor in breast cancer. UBA7 encodes an enzyme that catalyzes the covalent conjugation of the ubiquitin-like protein product of another ISG (ISG15) to cellular proteins in a process known as "ISGylation". ISGylation of other ISGs, including STAT1 and STAT2, synergistically facilitates production of chemokine-receptor ligands to attract cytotoxic T cells. These gene activation events are further linked to clustering and nuclear relocalization of STAT1/2 within IFN-induced PML bodies. Importantly, this coordinated ISG-ISGylation network plays a central role in suppressing murine breast cancer growth and metastasis, which parallels improved survival in breast cancer patients. These findings reveal a cooperative IFN-inducible gene network in orchestrating a tumor suppressive microenvironment.

[1]  E. Borden.  Interferons α and β in cancer: therapeutic opportunities from new insights , 2019, Nature Reviews Drug Discovery.

[2]  C. Horvath,et al.  Transcriptional and chromatin regulation in interferon and innate antiviral gene expression. , 2018, Cytokine & growth factor reviews.

[3]  J. Chang,et al.  Expansion microscopy , 2018, Journal of microscopy.

[4]  H. de Thé,et al.  PML nuclear bodies: from architecture to function. , 2018, Current opinion in cell biology.

[5]  A. Minn,et al.  Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. , 2018, Immunity.

[6]  T. Gajewski,et al.  Impact of oncogenic pathways on evasion of antitumour immune responses , 2018, Nature Reviews Cancer.

[7]  J. Clohessy,et al.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms , 2018, Nature Medicine.

[8]  Huanhuan Liang,et al.  NMI and IFP35 serve as proinflammatory DAMPs during cellular infection and injury , 2017, Nature Communications.

[9]  R. Young,et al.  A Phase Separation Model for Transcriptional Control , 2017, Cell.

[10]  Zhengdong D. Zhang,et al.  Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model , 2017, BMC Genomics.

[11]  T. Gajewski,et al.  Innate immune signaling and regulation in cancer immunotherapy , 2016, Cell Research.

[12]  H. Ishwaran,et al.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.

[13]  C. Caldas,et al.  Stratification and therapeutic potential of PML in metastatic breast cancer , 2016, Nature Communications.

[14]  R. Parker,et al.  Compositional Control of Phase-Separated Cellular Bodies , 2016, Cell.

[15]  Edward S Boyden,et al.  Protein-retention expansion microscopy of cells and tissues labeled using standard fluorescent proteins and antibodies , 2016, Nature Biotechnology.

[16]  G. Gloor,et al.  The Microbiota of Breast Tissue and Its Association with Breast Cancer , 2016, Applied and Environmental Microbiology.

[17]  L. Zitvogel,et al.  Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. , 2016, Cancer research.

[18]  Joshua C Vaughan,et al.  Expansion microscopy with conventional antibodies and fluorescent proteins , 2016, Nature Methods.

[19]  E. Wherry,et al.  Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling , 2016, Cell.

[20]  P. Hertzog,et al.  Optimizing mouse models for precision cancer prevention , 2016, Nature Reviews Cancer.

[21]  P. Brown,et al.  TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth , 2015, Proceedings of the National Academy of Sciences.

[22]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[23]  Jin-Hyun Ahn,et al.  Positive Role of Promyelocytic Leukemia Protein in Type I Interferon Response and Its Regulation by Human Cytomegalovirus , 2015, PLoS pathogens.

[24]  B. Faddegon,et al.  TH2-Polarized CD4+ T Cells and Macrophages Limit Efficacy of Radiotherapy , 2015, Cancer Immunology Research.

[25]  Edward S. Boyden,et al.  Expansion microscopy , 2015, Science.

[26]  K. Knobeloch,et al.  Selective inactivation of USP18 isopeptidase activity in vivo enhances ISG15 conjugation and viral resistance , 2015, Proceedings of the National Academy of Sciences.

[27]  J. Casanova,et al.  Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation , 2014, Nature.

[28]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[29]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[30]  Taro Kawai,et al.  Toll-Like Receptor Signaling Pathways , 2014, Front. Immunol..

[31]  L. Naldini,et al.  Genetic Engineering of Hematopoiesis for Targeted IFN-α Delivery Inhibits Breast Cancer Progression , 2014, Science Translational Medicine.

[32]  J. Stender,et al.  Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. , 2013, Molecular cell.

[33]  S. Kotenko,et al.  Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10 , 2013, EMBO molecular medicine.

[34]  S. Grant,et al.  Generation of high quality chromatin immunoprecipitation DNA template for high-throughput sequencing (ChIP-seq). , 2013, Journal of visualized experiments : JoVE.

[35]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[36]  Min-Sung Kim,et al.  Transient mammalian cell transfection with polyethylenimine (PEI). , 2013, Methods in enzymology.

[37]  J. Park,et al.  Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15. , 2012, The Journal of clinical investigation.

[38]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[39]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[40]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[41]  A. Haas,et al.  ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells , 2012, Experimental biology and medicine.

[42]  M. Loda,et al.  Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma , 2011, Journal of Virology.

[43]  L. Zitvogel,et al.  TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. , 2011, Cancer research.

[44]  Jian-Hua Tong,et al.  Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML , 2010, Science.

[45]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[46]  Andrea Falini,et al.  Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. , 2008, Cancer cell.

[47]  Peter A Fasching,et al.  The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer , 2008, Breast Cancer Research.

[48]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[49]  Ming Yan,et al.  Protein ISGylation modulates the JAK-STAT signaling pathway. , 2003, Genes & development.

[50]  Pier Paolo Pandolfi,et al.  The Role of PML in Tumor Suppression , 2002, Cell.

[51]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[52]  R. Krug,et al.  Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)‐induced ubiquitin‐like ISG15 protein , 2001, The EMBO journal.

[53]  François-Michel Boisvert,et al.  Promyelocytic Leukemia (Pml) Nuclear Bodies Are Protein Structures That Do Not Accumulate RNA , 2000, The Journal of cell biology.

[54]  J. Minna,et al.  Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene , 1998, Oncogene.